A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden

被引:151
|
作者
Le Gall, Celine
Bellahcene, Akeila
Bonnelye, Edith
Gasser, Juerg A.
Castronovo, Vincent
Green, Jonathan
Zimmermann, Johann
Clezardin, Philippe
机构
[1] Fac Med Laennec, INSERM, U664, IFR62, F-69372 Lyon 08, France
[2] Univ Lyon 1, F-69622 Villeurbanne, France
[3] Univ Liege, Metastasis Res Lab, Liege, Belgium
[4] Novartis Inst Biomed Res, Basel, Switzerland
关键词
D O I
10.1158/0008-5472.CAN-06-3940
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteoclasts mediate bone destruction in breast cancer skeletal metastases. Cathepsin K is a proteinase that is secreted by osteoclasts and degrades bone. Here, immohistochemistry revealed that cathepsin K was expressed not only by osteoclasts but also by breast cancer cells that metastasize to bone. Following intratibial injection with cathepsin K-expressing human BT474 breast cancer cells, tumor-bearing mice treated with a clinical dosing regimen of cathepsin K inhibitor (CKI; 50 mg/kg, twice daily) had osteolytic lesions that were 79% smaller than those of tumor-bearing mice treated with the vehicle. The effect of CKI was also studied in a mouse model in which the i.v. inoculation of human B02 breast cancer cells expressing cathepsin K leads to bone metastasis formation. Drug administration was started before (preventive protocol) or after (treatment protocol) the occurrence of osteolytic lesions. In treatment protocols, CKI (50 mg/kg, twice daily) or a single clinical dose of 100 mu g/kg zoledronic acid (osteoclast inhibitor) reduced the progression of osteolytic lesions by 59% to 66%. CKI therapy also reduced skeletal tumor burden by 62% compared with vehicle, whereas zoledronic acid did not decrease the tumor burden. The efficacy of CKI at inhibiting skeletal tumor burden was similar in the treatment and preventive protocols. By contrast, CKI did not block the growth of s.c. B02 tumor xenografts in animals. Thus, CKI may render the bone a less favorable microenvironment for tumor growth by inhibiting bone resorption. These findings raise the possibility that cathepsin K could be a therapeutic target for the treatment of bone metastases.
引用
收藏
页码:9894 / 9902
页数:9
相关论文
共 50 条
  • [1] Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis
    Silvia Marino
    Ryan T. Bishop
    Patrick Mollat
    Aymen I. Idris
    Calcified Tissue International, 2018, 103 : 206 - 216
  • [2] Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis
    Marino, Silvia
    Bishop, Ryan T.
    Mollat, Patrick
    Idris, Aymen I.
    CALCIFIED TISSUE INTERNATIONAL, 2018, 103 (02) : 206 - 216
  • [3] 2-Methoxyestradiol Analogue ENMD-1198 Reduces Breast Cancer-Induced Osteolysis and Tumor Burden Both In Vitro and In Vivo
    Snoeks, Thomas J. A.
    Mol, Isabel M.
    Que, Ivo
    Kaijzel, Eric L.
    Loewik, Clemens W. G. M.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (05) : 874 - 882
  • [4] Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor
    Chen, Yan
    Zheng, Jiehuang
    Mo, Lixia
    Chen, Fengsheng
    Li, Ruopeng
    Wang, Yiyuan
    Liang, Qinghe
    Chen, Ziye
    Dai, Wenqi
    Chen, Lishan
    Yan, Peiyu
    Zhou, Hua
    Li, Xiaojuan
    PHYTOMEDICINE, 2024, 129
  • [5] Epiberberine inhibits bone metastatic breast cancer-induced osteolysis
    Wei, Chengming
    Shi, Meina
    Wang, Zi
    Lan, Wenjian
    Feng, Na
    Zhang, Fuming
    Liu, Jiachen
    Lang, Jing-Yu
    Lin, Wanjun
    Ma, Wenzhe
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 327
  • [6] Use of serum markers of tumor burden and bone resorption to monitor disease progression in a nude mouse model of breast cancer-induced osteolysis.
    NicAmhlaoibh, R
    Risteli, J
    Holst-Hansen, C
    Qvist, P
    Christiansen, C
    Brünner, N
    Delaissé, J
    Heegaard, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S311 - S311
  • [7] Cathepsin K inhibitors for treating cancer-induced bone disease
    Clezardin, P.
    CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 : 15 - 15
  • [8] Longitudinal Monitoring of Breast Cancer-Induced Osteolysis in Aged Female Mice
    Wasi, Murtaza
    Wang, Shubo
    Xiong, Jinhu
    Geng, Fei
    You, Lidan
    Wang, Liyun
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 202 - 203
  • [9] Anti-resorptive and potential anti-invasion effects of a cathepsin K inhibitor in the treatment of breast cancer-induced bone metastasis
    Leung, Patrick
    Pickarski, Maureen
    Wesolowski, Gregg A.
    Duong, Le T.
    CANCER TREATMENT REVIEWS, 2008, 34 : S58 - S58
  • [10] Go6983 attenuates breast cancer-induced osteolysis by the apoptotic pathway
    Luan, Zhiwei
    Li, Jia
    Huang, Xing
    Feng, Wenyu
    Ma, Shiting
    Song, Fengyang
    Wu, Zhengyuan
    Zhang, Xiaohan
    Wei, Linfeng
    Yang, Zhenyi
    Yao, Jun
    CELL BIOLOGY INTERNATIONAL, 2020, 44 (03) : 838 - 847